Larimar Therapeutics (LRMR) Common Equity: 2013-2020
Historic Common Equity for Larimar Therapeutics (LRMR) over the last 7 years, with Sep 2020 value amounting to $102.6 million.
- Larimar Therapeutics' Common Equity rose 71.41% to $102.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $102.6 million, marking a year-over-year increase of 71.41%. This contributed to the annual value of -$694,000 for FY2019, which is 100.74% down from last year.
- As of Q3 2020, Larimar Therapeutics' Common Equity stood at $102.6 million, which was down 8.80% from $112.5 million recorded in Q2 2020.
- Over the past 5 years, Larimar Therapeutics' Common Equity peaked at $154.4 million during Q1 2016, and registered a low of -$694,000 during Q4 2019.
- Its 3-year average for Common Equity is $72.2 million, with a median of $72.1 million in 2019.
- Per our database at Business Quant, Larimar Therapeutics' Common Equity tumbled by 100.74% in 2019 and then soared by 71.41% in 2020.
- Quarterly analysis of 5 years shows Larimar Therapeutics' Common Equity stood at $121.7 million in 2016, then slumped by 35.74% to $78.2 million in 2017, then rose by 19.25% to $93.3 million in 2018, then tumbled by 100.74% to -$694,000 in 2019, then soared by 71.41% to $102.6 million in 2020.
- Its last three reported values are $102.6 million in Q3 2020, $112.5 million for Q2 2020, and $50.7 million during Q1 2020.